AstraZeneca Completes Global License Agreement for Oral EGFR Inhibitor Zefrovy for Lung Cancer
September 02, 2026
September 02, 2026
WILMINGTON, Delaware, Sept. 2 -- AstraZeneca, a biopharmaceutical company, issued the following news release on Sept. 1, 2026:
* * *
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY(R) (sunvozertinib) for lung cancer
AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY(R) (sunvozertinib), an oral irreversible epidermal grow . . .
* * *
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY(R) (sunvozertinib) for lung cancer
AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY(R) (sunvozertinib), an oral irreversible epidermal grow . . .